Plasma Tissue Factor Pathway Inhibitor Levels as a Marker for Postoperative Bleeding After Enoxaparin Use in Deep Vein Thrombosis Prophylaxis in Orthopedics and General Surgery

Clinical and Applied Thrombosis/Hemostasis

Volumn 7, Issue 1, 2001, Pages 65-71

  Hakki, Sam I ^a   Fareed, Jawed ^b   Hoppensteadt, Debra A ^b   Abdullah, Hani ^c   Camblin, John ^a   Nasseri, Andrew F ^a   Hamadeh, Ossama ^c   Wright, Terry ^c  

^a Bay Pines Medical Center   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Enoxaparin; Postoperative bleeding; Tissue factor pathway inhibitor

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEMOGLOBIN; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR;

ARTHROPLASTY; ARTICLE; BLOOD; BLOOD CLOTTING TEST; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLON RESECTION; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; HUMAN; METABOLISM; METHODOLOGY; ORTHOPEDIC SURGERY; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDY; SURGERY; VEIN THROMBOSIS;

ANTICOAGULANTS; ARTHROPLASTY; BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; COLECTOMY; DOUBLE-BLIND METHOD; ENOXAPARIN; FACTOR XA; HEMOGLOBINS; HUMANS; LIPOPROTEINS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; SURGICAL PROCEDURES, OPERATIVE; VENOUS THROMBOSIS;

EID: 0035235599     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960100700113     Document Type: Article

References (45)

1. Hoppensteadt DA, Walennga JM, Fasanella A., Jeske J., Fareed J. Antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res. 1995; 77(2)-175.
2. Holst J., Lindblad B., Mattiasson SE, Stjemquist U., Ezban M., Ostergaard PB, Hedner U. Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin. Thromb Haemost. 1996; 74(4): 585.
3. Hansen JB, Sandset PM, Huseby KR, Huseby NE, Beendz B. Ostergaard P, Nordoy A. Differential effect of unfractionated heparin and low molecular weight heparin on intravenous tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol 1998;101(4):638.
4. Bara L., Planes A., Samama M. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, witi-Ilaa activities, and D-dimer plasma levels in pationts receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999; 104(2):230.
5. Horlocker TT, Wedel DJ Neuraxial block and low-molecular weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med. 1998; 23(Suppl 2):164.
6. Eriksson BI, Katebo P., Anthmyr BA, Wadenvik H., Tengbor L., Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg. 1991; 73(4):484.
7. Samama MM, Bara L., Gerotziafas GT Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994: 24: 105.
8. Bara L., Bloch MF, Zitoun D., et al. Comparative effects of Enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res. 1993; 69(5): 443.
9. Kijowski R., Hoppensteadt D., walenga J., Borris L., Lassen MR, Fareed J. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxsis in patients treated with low molecular weight heparin. Thromb Res. 1994; 74(1):53.
10. Bajaj MS, Bajaj SP Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost. 1997; 78(1):471.
11. Ariens RAS, Alberio G., Moia M., Mannucci PM Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost. 1999;81(2):203.
12. Holst J., Lindblad B., Matthiasson SE, Stjernquist U., Ezban M., Ostergaard PB, Hedner U. Experimental haemorrhagic effect of two domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin. Thromb Haemost. 1996; 75 (4):585.
13. Spiro TE, Fitzgerald RH, Trowbridge AA, et al. for the Enoxaparin Clinical Trial Group. Enoxaparin, a low molecular weight heparin and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery. Blood 1994; 84(Suppl): 246a.
14. Colwell CW, Haas SB, Lotke PA, Paiement GD, Sculco TP Thromboembolic disease in orthopaedic surgery. American Academy of Orthopaedic Surgeons 65th Annual Meeting. Instructional Course Lectures Handout Cover, Course Number: 132.
15. Bierbaum BE, Callaghan JC, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg. 1999; 81: 2.
16. Kessler CM, Esparraguera IM, Jacobs HM, et al. Monitoring the anticoagulanat effects of a low molecular weight heparin preparation. Coagulation Transfusion Med. 1995; 103(5):642.
17. Abbate R., Gori AM, Farsi A., Attanasio M., Pepe G. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol. 1998; 82(5):33L.
18. Hamulyak K., Lensing AWA, Van der Meer J., Smid WM, Van Ooy A., Hoek JA Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in effective hip and knee replacement? Thromb Haemost. 1994;74(6): 1428.
19. Shaieb MD, Watson BN, Atkinson RE Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis. J Ar— throplasty 1999; 14(4):432.
20. Spiro TE, Colwell CW Efficacy and safety of enoxaparin for the prevention of deep vein thrombosis after hip replacement surgery. Orthop Rev 1994; XXIII(3):47.
21. Turpie AGG, Levine MN, Hirsh J., et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. Heparin Deep-Vein Thromb 1986;315(15):925.
22. Planes A., Vochelle N., Fagola M., Feret J., Bellaud M. Prevention of deep vein thrombosis after total hip replacement. J Bone Joint Surg. 1991; 73(3):418.
23. Erikson BI, Kalebo P., Anthmyr BA, Wadenvik H., Tengbom L., Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg. 1991; 73(4):484.
24. Francis CW, Pellegrini VD, Totterman S., et al. Prevention of deep-vein thrombosis after total hip replacement. J Bone Joint Surg. 1997; 79(9):1365.
25. Kakkar VV, Corrisan T., Spindler J., Fossard DP, Flut PT Efficacy of low doses of heparin in prevention of deep vein thrombosis after major surgery: a double-blind randomized study. Lancet 1972; 1: 101.
26. Mcnally MA, Cooke EA. Harding ML, Mollan RA. Attitudes to, and utilization of, low molecular weight heparins in joint replacement surgery. J R Coll Surg Edinb 1997; 42(6):407.
27. Fareed J., et al. Tissue factor antigen levels in various biological fluids. Blood Coagulation Fibrinolysis 1995; 6: 1.
28. Bang CJ, Berstad A., Tatstad I. Haemorrhagic effects of unfractionated and two low molecular weight heparins, enoxaparin and fragmin, in rats. Haemostasis 1901; 21(1):30.
29. Eriksson BI Soderberg K., Widlund L., Wandeli B. Tengborn L., Risberg B. A comparison study of three low-molecular weight hephrins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost. 1995: 73(3):398.
30. Planes A., Vochelle N., Fagola M., Bellaud M. Comparison of two low-molecular-weight heparin for the prevention of postoperative venous thromboembotism after elective hip surgery. Reviparin Study Group. Blood Coagulation Fibrinolysis 1998; 9(6):499.
31. Barsotti J., Gruel Y., Rosset P., et al. Comparative double-blind study of two dosage regimens of low-molecular weight heparin in elderly patients with a fracture of the neck of the femur. J Orthop Trauma 1990; 4(4):371.
32. Gjengedal E., Uppheim G. Clexane (enoxaparin) or Fragmin (dalteparin) for thrombolytic prevention in hip replacement surgery? Tidsskr Nor Laegeforen 1996; 116(15):1782.
33. Hamamoto T., Kisiel W. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Blood Coagulation Fibrinolysis 1996; 7(4):470.
34. Bick RL, et al. Heparin realistic tissue factor pathway inhibitor during interventional cardiovascular procedures. Blood 1994; 84: 81.
35. Fareed J., et al. Platelet factor 4 and antithrombin are not the sole determinants of the heparinzation response. Circulation 1994; 90; 180.
36. Ostergaard P., Nordfang O., Peterson LC, Valentin S., Kristensen H. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Haemostasis 1993; 23(Suppl 1):107.
37. Hoppensteadt DA, Jeske W., Fareed J., Bermes EW The role of tissue factor pathway inhibitor in the medication of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagulation Fibrinolysis 1995;6(Suppl 6):S57.
38. Jeske W., Hoppensteadt D., Callas D., Koza MJ, Fareed J. Pharmacological profiling of recombinant tissue factor pathway inhibitor. Thromb Hemost. 1996; 22(2):213.
39. Hamamoto T., Kisiel W. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Blood Coagulation Fibrinolysis 1996; 7(4):470.
40. Hamamoto T., Kisiel W. Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin. Thromb Res. 1995; 80(4):291.
41. Gouin-Thibault I., Dewar L., Craven S., Kulczcky M. Wun TC, Ofosu FA Probable regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo. Br J Haematol 1996; 95(4):738.
42. Kaiser B., Hoppensteadt DA, Jeske W., Wun TC, Fareed J. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans. Thromb Res. 1994; 75(6):609.
43. van't Veer C., Mann KG Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem. 1997; 272(7):4367.
44. Hoppensteadt DA, Jeske W., Fareed J., Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagulation Fibrinolysis 1995;6(Suppl 1):S57.
45. Kijowski R., Hoppensteadt D., Walenga J., Borris L., Lassen MR, Fareed J. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin. Thromb Res. 1994; 74(1):53.